ABOUT US

about us

Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

RESEARCH REPORTS

RESEARCH REPORTS

Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

METHODOLOGY

METHODOLOGY

Azoth Analytics creates in-depth research reports by recording, interpreting and analyzing information through primary and secondary research. Our strategic market sizing and data dredging techniques include secondary research, interviews with key market players and industry experts and use of industry specific statistical tools which helps in designing and planning effective research for our global and local clients.

Consulting

Consulting

Azoth Analytics Consulting assists clients across the globe to enter, progress, and develop in the targeted market through our fact-based business intelligence. We deliver practical and implementable solutions to our domestic and international clients. Our analysts are skilled with techniques of data gathering, market sizing, forecasting, analyzing and providing competitive intelligence and provide progressive research in verticals including healthcare & pharmaceutical...

media center

media center

Our business research and market analysis helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

Among the drugs in the Antibody Drug Conjugates (ADC), Adcetris will witness faster growth than Kadcyla

Date: 25 March 2017

Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.

Globally, only two ADCs are present in the market – Adcetris and Kadcyla. Adcetris was approved by FDA in 2011 and Kadcyla in 2013. Mylotarg, a drug developed by Pfizer, was the first ADC ever approved but was voluntarily withdrawn from the market in 2010 but is still available in Japan. Approval and successful commercialization of Adcetris and Kadcyla have made the biopharmaceutical market realise the immense potential that ADC holds. There has been heavy investment in the development of ADCs by leading biotechnology and biopharmaceutical companies with about 50 molecules presently in the clinical development stage and more than 190 trials taking place around the world. Several molecules are currently in late stage of clinical trials and are expected to gain approval and enter market in next few years which will result in heavy growth of global ADC market. Companies have been strategically expanding their market through multiple licensing of proprietary ADC technology, and collaboration amongst companies for developing ADCs. Major trend that the ADC market has been witnessing over the years is outsourcing of ADC production to CMOs (Contract Manufacturing Organisation)

Among the drugs, Adcetris will witness faster growth than Kadcyla as the former is expecting approval for more indications in the forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years